These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 29067290)

  • 1. Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease.
    Satlin A; Wang J; Logovinsky V; Berry S; Swanson C; Dhadda S; Berry DA
    Alzheimers Dement (N Y); 2016 Jan; 2(1):1-12. PubMed ID: 29067290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
    Swanson CJ; Zhang Y; Dhadda S; Wang J; Kaplow J; Lai RYK; Lannfelt L; Bradley H; Rabe M; Koyama A; Reyderman L; Berry DA; Berry S; Gordon R; Kramer LD; Cummings JL
    Alzheimers Res Ther; 2021 Apr; 13(1):80. PubMed ID: 33865446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Bayesian adaptive dose selection procedure with an overdispersed count endpoint.
    Pozzi L; Schmidli H; Gasparini M; Racine-Poon A
    Stat Med; 2013 Dec; 32(28):5008-27. PubMed ID: 24022748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A combined proof of concept and dose finding study with multiple endpoints: A Bayesian adaptive design in chronic prostatitis/chronic pelvic pain syndrome.
    Martina R; Houbiers J; Melis J; van Till O
    Biom J; 2019 May; 61(3):476-487. PubMed ID: 30178528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do we need to adjust for interim analyses in a Bayesian adaptive trial design?
    Ryan EG; Brock K; Gates S; Slade D
    BMC Med Res Methodol; 2020 Jun; 20(1):150. PubMed ID: 32522284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.
    Smith CL; Jin Y; Raddad E; McNearney TA; Ni X; Monteith D; Brown R; Deeg MA; Schnitzer T
    Pharm Stat; 2019 Jan; 18(1):39-53. PubMed ID: 30321909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian dose selection design for a binary outcome using restricted response adaptive randomization.
    Meinzer C; Martin R; Suarez JI
    Trials; 2017 Sep; 18(1):420. PubMed ID: 28886745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian Adaptive Randomization and Trial Monitoring with Predictive Probability for Time-to-event Endpoint.
    Yin G; Chen N; Lee JJ
    Stat Biosci; 2018 Aug; 10(2):420-438. PubMed ID: 30559900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer's disease.
    Dhadda S; Kanekiyo M; Li D; Swanson CJ; Irizarry M; Berry S; Kramer LD; Berry DA
    Alzheimers Res Ther; 2022 Dec; 14(1):182. PubMed ID: 36482412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interim futility analysis with intermediate endpoints.
    Goldman B; LeBlanc M; Crowley J
    Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Bayesian vs Frequentist Adaptive Trial Design in the Stroke Hyperglycemia Insulin Network Effort Trial.
    Broglio K; Meurer WJ; Durkalski V; Pauls Q; Connor J; Berry D; Lewis RJ; Johnston KC; Barsan WG
    JAMA Netw Open; 2022 May; 5(5):e2211616. PubMed ID: 35544137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and Design of an Adaptive Phase 2b/3 Clinical Trial of Selepressin for Adults in Septic Shock. Selepressin Evaluation Programme for Sepsis-induced Shock-Adaptive Clinical Trial.
    Lewis RJ; Angus DC; Laterre PF; Kjølbye AL; van der Meulen E; Blemings A; Graves T; Russell JA; Carlsen JE; Jacobsen K; Yealy DM; Opal SM; Windeløv NA; François B; Perner A; Pickkers P; Berry SM
    Ann Am Thorac Soc; 2018 Feb; 15(2):250-257. PubMed ID: 29388815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel Bayesian adaptive design incorporating both primary and secondary endpoints for randomized IIB chemoprevention study of women at increased risk for breast cancer.
    Gajewski BJ; Kimler BF; Koestler DC; Mudaranthakam DP; Young K; Fabian CJ
    Trials; 2022 Dec; 23(1):981. PubMed ID: 36471449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency.
    Collignon O; Koenig F; Koch A; Hemmings RJ; Pétavy F; Saint-Raymond A; Papaluca-Amati M; Posch M
    Trials; 2018 Nov; 19(1):642. PubMed ID: 30454061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive, dose-finding phase 2 trial evaluating the safety and efficacy of ABT-089 in mild to moderate Alzheimer disease.
    Lenz RA; Pritchett YL; Berry SM; Llano DA; Han S; Berry DA; Sadowsky CH; Abi-Saab WM; Saltarelli MD
    Alzheimer Dis Assoc Disord; 2015; 29(3):192-9. PubMed ID: 25973909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An adaptive clinical trial design to identify the target dose of tenecteplase for treatment of acute pulmonary embolism.
    Yeatts SD; Foster LD; Barsan WG; Berry NS; Callaway CW; Lewis RJ; Saville BR; Silbergleit R; Kline JA
    Clin Trials; 2022 Dec; 19(6):636-646. PubMed ID: 35786002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety.
    Teramukai S; Daimon T; Zohar S
    Stat Med; 2015 Sep; 34(22):3029-39. PubMed ID: 26038148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design considerations and analysis planning of a phase 2a proof of concept study in rheumatoid arthritis in the presence of possible non-monotonicity.
    Liu F; Walters SJ; Julious SA
    BMC Med Res Methodol; 2017 Oct; 17(1):149. PubMed ID: 28969588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial design with Bayesian adaptive randomization and predictive probability.
    Yin G; Chen N; Lee JJ
    J R Stat Soc Ser C Appl Stat; 2012 Mar; 61(2):219-35. PubMed ID: 24259753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A proof-of-concept-to-confirmatory multiple adaptation design in the development of an anti-viral treatment.
    Fan XF; Gallo P; Su G; Menton R; Segal F
    Stat Methods Med Res; 2019 Dec; 28(12):3491-3501. PubMed ID: 30375280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.